Fluorine As Only Halogen Patents (Class 514/759)
  • Patent number: 6514963
    Abstract: The present invention comprises methods and compositions for use in inhibiting egg production by parasitic trematode worms comprising administering to an individual in need thereof an effective amount of an agent which transiently inhibits the influx of calcium through a cell membrane calcium channel. Inhibition of egg production in the worms ameliorates many of the symptoms and pathology related to infection by trematode related diseases, including Schistosomiasis. The methods can also effect disease transmission by reducing the number of eggs released into the environment available to continue the worm life cycle.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: February 4, 2003
    Assignee: The Regents of the University of California
    Inventors: Mark Walter, Armand Kuris
  • Patent number: 6495607
    Abstract: Benzocycloheptenes of general formula I in which R1, R2 and Y have the meanings indicated herein, have antiestrogenic activity on and are suitable for the production of pharmaceutical agents, especially for prophylaxis and therapy of osteoporosis.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: December 17, 2002
    Assignee: Schering AG
    Inventors: Rolf Bohlmann, Jorg Kroll, Hermann Kuenzer, Christa Hegele-Hartung, Monika Lessl, Rosemarie Lichtner, Yukishige Nishino
  • Patent number: 6486212
    Abstract: The invention concerns semi-fluorinated alkanes of the general formulae RFRH or RFRHRF, RF being a linear or branched perfluoroalkyl group and RH being a linear or branched saturated (hydrocarbon)-alkyl group.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: November 26, 2002
    Inventor: Hasso Meinert
  • Patent number: 6472437
    Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWAs). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: October 29, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Ernest H. Braue, Jr., Stephen T. Hobson, Erich K. Lehnert
  • Patent number: 6472438
    Abstract: A topical skin protectant formulation containing a barrier cream and a reactive moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and a reactive moiety that serves to neutralize chemical warfare agents into less toxic agents.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: October 29, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Ernest H. Braue, Jr., Millard M. Mershon, Catherine R. Braue, Ruth A. Way
  • Publication number: 20020137803
    Abstract: This invention relates to a non-aqueous fluorocarbon composition for use in magnetic resonance imaging (MRI) or radiographic imaging (X-ray or computed tomography), particularly imaging of the gastrointestinal (GI) tract; an improved fluorocarbon composition with enhanced contrast effects in the GI tract; a fluorocarbon composition having improved palatability; a fluorocarbon composition for delivering drugs or bioactive agents; improved preparations for radiographic imaging or MRI; methods for producing and using such preparations; methods for improving the palatability of non-aqueous liquids; and methods for improving imaging.
    Type: Application
    Filed: February 15, 2002
    Publication date: September 26, 2002
    Inventor: W. Dean Kirkland
  • Patent number: 6437005
    Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWAs). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: August 20, 2002
    Assignees: The United States of America as represented by the Secretary of the Army, Mainstream Engineering Corporation
    Inventors: Stephen T. Hobson, Ernest H. Braue, Jr., Dwight Back
  • Publication number: 20020111386
    Abstract: A hyperthermic treatment of lung cancer in a patient and delivering therapeutic or diagnostic biological agents to airway surfaces, where preselected pulmonary air passages adjoining pulmonary tissues comprising malignant cells are temporarily filled and then heating adjoining pulmonary tissues comprising the malignant cells to a temperature in a specified range by transmitting ultrasound through the liquid-filled pulmonary passages of a specific frequency. Also disclosed is an apparatus for applying the ultrasound at the appropriate frequency to the interior surfaces of a bodily cavity for diagnostic and therapeutic treatment.
    Type: Application
    Filed: April 5, 2002
    Publication date: August 15, 2002
    Inventors: K. Michael Sekins, Thomas H. Shaffer, Marla R. Wolfson
  • Publication number: 20020103222
    Abstract: A method of preserving tissue by placing the tissue in a media containing pure perfluorocarbon is provided. Also provided is a tissue preserving media including storage media and pure perfluorocarbon. A method of making media by adding pure perfluorocarbon to the media is provided. A method of preserving tissue by oxygenating the storage media by adding pure perfluorocarbons to the media is also provided.
    Type: Application
    Filed: November 29, 2001
    Publication date: August 1, 2002
    Inventor: Harpal S. Mangat
  • Patent number: 6420434
    Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: July 16, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Ernest H. Braue, Jr., Stephen T. Hobson, James White, Richard Bley
  • Patent number: 6417236
    Abstract: A topical skin protectant formulation containing a barrier cream and an active hybrid organic-inorganic polysilsesquioxane material for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: July 9, 2002
    Assignees: The United States of America as represented by the Secretary of the Army, The Regents of the University of California
    Inventors: Stephen T. Hobson, Ernest H. Braue, Kenneth Shea
  • Patent number: 6414039
    Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: July 2, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Ernest H. Braue, Jr., Stephen T. Hobson, Craig L. Hill, Eric Boring, Jeff Rhule
  • Patent number: 6410604
    Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: June 25, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Ernest H. Braue, Jr., Stephen T. Hobson, Chandrike Govardhan, Nazar Khalaf
  • Patent number: 6410603
    Abstract: A topical skin protectant formulation containing a barrier cream and a active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWAs). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: June 25, 2002
    Assignees: The United States of America as represented by the Secretary of the Army, Nanoscale Materials, Inc., Emory University
    Inventors: Stephen T. Hobson, Ernest H. Braue, Erich K. Lehnert, Kenneth J. Klabunde, Shawn Decker, Craig L. Hill, Jeffrey Rhule, Eric Boring, Olga Koper
  • Publication number: 20020077368
    Abstract: Methods for the diagnosis and treatment of articular disorders comprising the use of fluorocarbons are disclosed. The methods provide for the introduction of a fluorocarbon into an articular region to replace or augment natural synovial fluid. The introduced fluorocarbons, which may be in various forms including liquids, gels or emulsions, provide articular lubrication and cushioning which is effective for the treatment of disorders such as osteoarthritis and rheumatoid arthritis. Additionally, the methods of the present invention may be used to provide high resolution articular images, reduce articular inflammation and introduce bioactive agents to the articular region.
    Type: Application
    Filed: November 12, 2001
    Publication date: June 20, 2002
    Inventors: Mark A. Walters, Ronald M. Hopkins, David H. Klein
  • Patent number: 6403653
    Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: June 11, 2002
    Assignees: The United States of America as represented by the Secretary of the Army, Nanoscale Materials, Inc.
    Inventors: Stephen T. Hobson, Ernest H. Braue, Jr., Erich K. Lehnert, Kenneth J. Klabunde, Olga P. Koper, Shawn Decker
  • Publication number: 20020068765
    Abstract: This invention describes the new benzocycloheptenes of general formula I 1
    Type: Application
    Filed: July 19, 1999
    Publication date: June 6, 2002
    Inventors: ROLF BOHLMANN, JORG KROLL, HERMANN KUENZER, CHRISTA HEGELE-HARTUNG, MONIKA LESSL, ROSEMARIE LICHTNER, YUKISHIGE NISHINO
  • Patent number: 6375962
    Abstract: Skin protection agents such as topical compositions which can prevent the passage of toxic chemicals through the skin, such as barrier creams. Formulations may contain hexamethylene tetramine or derivatives or analogues thereof, which react with alkylating agents such as sulfur mustard, and which are suitable for formulation into topical compositions. The formulations additionally may contain perfluorinated polymeric compounds which are effective barrier compounds for a range of toxic chemicals.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: April 23, 2002
    Assignee: The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland
    Inventors: John Jenner, Colin N Smith, Robert P Chilcott, Christopher D Lindsay
  • Patent number: 6322800
    Abstract: A fluorohydrocarbon compound of formula RF—C2H4—O—CO—RH, in which RF is a perfluorinated alkyl group and RH is an alkyl group, in and/or for the preparation of a stable emulsion containing at least one fatty phase and one aqueous phase. The invention also relates to the use of the same compound as a stabilizing agent for an emulsion containing at least one fatty phase and one aqueous phase. Another subject of the invention is the use of such a compound as an essential component of the fatty phase of an emulsion and emulsions containing such a fatty phase. Another subject of the invention is a composition comprising such an emulsion.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: November 27, 2001
    Assignee: L'Oreal S.A.
    Inventors: Michel Philippe, Jean-Christophe Henrion, Luc Nicolas-Morgantini, Agn├Ęs Dardenne, Eric Bollens
  • Patent number: 6315756
    Abstract: Compositions of perfluorocarbons and methods of using these compositions for subcutaneous fat removal. A version of the composition also contains local anesthetic and/or vasoconstrictors. The composition is in association with a pharmacuetical carrier. The composition is for use in liposuction techniques. Also provided is a method for subcutaneous removal of lipid or fat cells from a patient using the composition.
    Type: Grant
    Filed: January 13, 2000
    Date of Patent: November 13, 2001
    Inventor: Nikolai Tankovich
  • Patent number: 6274633
    Abstract: The present invention relates to the use of xenon as an NMDA antagonist. In particular, the invention relates to a method of treatment comprising modulating the activity of an NMDA receptor in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon. In a further aspect, the invention provides a process for the preparation of a pharmaceutical composition suitable for modulating the activity of an NMDA receptor.
    Type: Grant
    Filed: August 23, 1999
    Date of Patent: August 14, 2001
    Assignee: Imperial College of Science, Technology, and Medicine
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • Patent number: 6242472
    Abstract: Methods of delivering a therapeutic or diagnostic agent in a perfluorochemical liquid carrier are provided. In preferred embodiments, the disclosed methods use compositions in the form of an emulsion or a dispersion for delivery of a biological agent to the pulmonary air passages.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: June 5, 2001
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: K. Michael Sekins, Thomas H. Shaffer, Marla R. Wolfson
  • Patent number: 6224851
    Abstract: The present invention provides a process for making transfer resistant make-up or sun-screen cosmetic compositions containing particles, which process includes introducing at least one volatile polyorganohalogen solvent, the halogen atom being fluorine, as an anti-transfer agent.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: May 1, 2001
    Assignee: L'Oreal
    Inventor: Isabelle Bara
  • Patent number: 6224885
    Abstract: The present invention relates to protection agents, in particular to topical compositions such as barrier creams which can prevent the passage of toxic chemicals and chemical warfare agents through the skin. Formulations contain hexamethylene tetramine derivatives or analogues thereof and perfluorinated polymeric compounds.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: May 1, 2001
    Assignee: The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland
    Inventors: John Jenner, Colin N Smith, Robert P Chilcott, Christopher D Lindsay
  • Patent number: 6204296
    Abstract: Storage stable fluorocarbon emulsions having a continuous aqueous phase and a discontinuous fluorocarbon phase, in which the fluorocarbon phase comprises a major amount of a first fluorocarbon or fluorocarbon mixture, and a minor amount of a second fluorocarbon or fluorocarbon mixture, in which the second fluorocarbon has a molecular weight greater than that of the first fluorocarbon and the second fluorocarbon includes a lipophilic moiety in its structure, whereby the second fluorocarbon serves to promote particle size stability in the emulsion while simultaneously providing favorably short organ retention times when administered to animals in vivo.
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: March 20, 2001
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Jeffry Greg Weers, David Henry Klein, Cindy Shizuko Johnson
  • Patent number: 6136331
    Abstract: A cosmetic containing fluorine-containing oil represented by the following formula do not inhibit the oil repellency of powder treated with a fluorine-containing compound, is excellent in affinity for the skin, and is inexpensive.
    Type: Grant
    Filed: December 29, 1998
    Date of Patent: October 24, 2000
    Assignee: Daikin Industries LTD
    Inventors: Masamichi Morita, Eiji Seki, Motonobu Kubo
  • Patent number: 6113919
    Abstract: Fluorocarbon emulsions comprising a stabilizing, particle size controlling fluorophilic/hydrophilic compound which can have the formulaR.sub.F.sup.1 --W--R.sub.H.sup.1 (I)whereinR.sub.F.sup.1 is a linear, branched or cyclic C.sub.2-14 fluorocarbon group;R.sub.H.sup.1 is a linear, branched or cyclic C.sub.2-18 saturated or unsaturated hydrocarbon group; andW is absent or is a bivalent species chosen from the group consisting of --O--, --S--, or various fluorinated structures. Use of the fluorophilic/lipophilic compound in the dispersions of the invention provides stable particle size and efficient emulsification. The dispersions of the invention can comprise biologically useful additive and can be used for various purposes, as oxygen carriers, contrast agents, or diagnostic agents.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 5, 2000
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Jean G. Reiss, Michele Postel, Luis Sole-Violan, Marie-Pierre Krafft, Chantal Cornelus
  • Patent number: 6008209
    Abstract: This invention provides a method of treating or preventing neoplastic diseases. The method comprises adminstering to a host in need of such treatment or prevention an effective amount of a Vitamin D.sub.3 analog of the Formula I wherein:X is H.sub.2 or CH.sub.2 ;Y is hydrogen, hydroxy or fluorine;Z is hydroxy;R.sub.1 and R.sub.2 are a (C.sub.1 -C.sub.4) alkyl or fluoroalkyl, or R.sub.1 and R.sub.2 together with C.sub.25 form a (C.sub.3 -C.sub.6) cycloalkyl or cyclofluoroalkyl;R.sub.3 and R.sub.4 are a (C.sub.1 -C.sub.4) alkyl or fluoroalkyl, or R.sub.3 and R.sub.4 together with C.sub.25' form a (C.sub.3 -C.sub.6)cycloalkyl or cyclofluoroalkyl;A is a single bond or a double bond;B.sub.1 is a single bond, an E-double bond, a Z-double bond or a triple bond; andB.sub.2 is a single bond, an E-double bond, a Z-double bond or a triple bond; or a prodrug thereof.
    Type: Grant
    Filed: April 16, 1998
    Date of Patent: December 28, 1999
    Assignees: Hoffmann-La Roche Inc., Syntex (U.S.A.)
    Inventors: Percy Sarwood Manchand, Milan Radoje Uskokovic
  • Patent number: 5989918
    Abstract: A method for analyzing the ADME/PK properties of a mixture of compounds is (1) perfusing an animal or organ with a perfluorocarbon emulsion blood substitute, (2) administering the mixture of test compounds, (3) withdrawing an aliquot of the perfusate, (4) disrupting the emulsion, and (5) analyzing the aqueous phase of the perfusate for the concentration of test compounds.
    Type: Grant
    Filed: August 28, 1997
    Date of Patent: November 23, 1999
    Assignee: Chiron Corporation
    Inventors: Corine M. Dietz, Jacqueline A. Gibbons, Eric W. Taylor
  • Patent number: 5955439
    Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation and in particular to a pharmaceutical aerosol formulation which comprises (a) particulate medicament; (b) at least one sugar; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: September 21, 1999
    Assignee: Glaxo Group Limited
    Inventor: Alexander Peter Green
  • Patent number: 5914352
    Abstract: Storage stable fluorocarbon emulsions having a continuous aqueous phase and a discontinuous fluorocarbon phase, in which the fluorocarbon phase comprises a major amount of a first fluorocarbon or fluorocarbon mixture, and a minor amount of a second fluorocarbon or fluorocarbon mixture, in which the second fluorocarbon has a molecular weight greater than that of the first fluorocarbon and the second fluorocarbon includes a lipophilic moiety in its structure, whereby the second fluorocarbon serves to promote particle size stability in the emulsion while simultaneously providing favorably short organ retention times when administered to animals in vivo.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: June 22, 1999
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Jeffry Greg Weers, David Henry Klein, Cindy Shizuko Johnson
  • Patent number: 5911973
    Abstract: The invention relates to a film-forming composition, which may be used as a mascara, an eye-liner, a nail varnish or a lacquer, in an aqueous medium, containing, in dispersed form, at least one film-forming material and a fluoro copolymer resulting from the copolymerization of at least a first fluorovinyl monomer and at least a second monomer of formula (A): ##STR1## where R.sub.1 represents a hydrogen atom or a C.sub.1 to C.sub.4 alkyl radical and R.sub.2 represents a C.sub.1 to C.sub.6 alkyl radical, a C.sub.2 to C.sub.4 hydroxycarbon radical or a radical --(CH.sub.2).sub.p --NH--R.sub.3, where R.sub.3 represents a C.sub.1 to C.sub.6 alkyl or a cycloalkyl and p is an integer ranging from 1 to 4.
    Type: Grant
    Filed: May 22, 1996
    Date of Patent: June 15, 1999
    Assignee: L'Oreal
    Inventor: Valerie de la Poterie
  • Patent number: 5869539
    Abstract: The present invention involves perfluoro compound emulsions including nitric oxide, their preparation and their use. These emulsions provide a new source of nitric oxide. Such nitric oxide-containing emulsions may be used for the administration of nitric oxide to individuals in need thereof. Individuals in need of nitric oxide administration can include those suffering from hypertension, preeclampsia and a number of other situations where an increased blood flow, for example, is desirable. In addition, given the long use of perfluoro compound emulsions as blood substitutes, the present invention provides a relatively safe mode for administering and distributing nitric oxide-without potential negative side effects such as toxicities due to drug metabolites.
    Type: Grant
    Filed: April 17, 1996
    Date of Patent: February 9, 1999
    Assignees: Board of Regents, The University of Texas System, The Texas A&M University System
    Inventors: R. E. Garfield, A. T. Balaban, W. A. Seitz
  • Patent number: 5859068
    Abstract: A method for the acceleration of tissue growth using continuous fluorocarbon liquid-based positive pressure is disclosed, whereby significant increase in tissue growth is achieved.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: January 12, 1999
    Assignee: Children's Medical Center Corporation
    Inventor: Jay M. Wilson
  • Patent number: 5851544
    Abstract: Cosmetic skin or hair care compositions containing a liquid, inert, hydrophobic fluorocarbon infused with carbon dioxide. The compositions increase blood flow to the skin, thus increasing endogenous oxygen and nutrient delivery to the skin.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: December 22, 1998
    Assignee: Chesebrough-Pond's USA Co., Division of Conopco, Inc.
    Inventors: Christine Penska, Uma Santhanam, Stephan Habif
  • Patent number: 5840767
    Abstract: Perfluorotetramethylcyclohexane shows improved properties for use in biological gas exchange, both as a blood substitute and as perfluorocarbon for intra-pulmonary applications. The material has an adequately low vapor pressure to completely avoid causing hyperinflated lung damage and to increase the interval between required applications. However, the compound has a sufficiently high vapor pressure to produce acceptably brief residence time within the body. A method has been developed for using this novel compound to accelerate the exhalation of very low vapor pressure compounds such as perfluorophenanthrene from the lungs. The addition of perfluorotetramethylcyclohexane, along with perfluorophenanthrene, greatly increases the rate at which the perfluorophenanthrene is exhaled.
    Type: Grant
    Filed: December 1, 1995
    Date of Patent: November 24, 1998
    Assignee: Synthetic Blood International, Inc.
    Inventor: Leland C. Clark, Jr.
  • Patent number: 5833997
    Abstract: Fluorinated hydrocarbon compounds have formula (I):R.sub.F --(CH.sub.2).sub.n --X--?C.sub.3 H.sub.5 (OH)!--(Y).sub.x --R.sub.H ,in which C.sub.3 H.sub.5 (OH) represents structures (Ia) or (Ib): ##STR1## R.sub.F is a perfluorinated C.sub.4 -C.sub.20 alkyl radical or a mixture of perfluorinated C.sub.4 -C.sub.20 radicals; R.sub.H is a straight or branched C.sub.1 -C.sub.22 alkyl radical or a mixture of straight or branched C.sub.1 -C.sub.22 alkyl radicals or an aryl or aralkyl radical; n is from 0 to 4; X stands for O, S, ##STR2## x stands for 0 or 1; Y stands for O, S, (a) or (b); with the proviso that when X.dbd.S, (a) or (b), Y is not S, (a) or (b). The use of said compounds as amphiphilic compounds, the method of preparing them, and the cosmetic compositions containing them are also disclosed.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: November 10, 1998
    Assignee: L'Oreal
    Inventors: Claude Mahieu, Eric Bollens, Myriam Mellul
  • Patent number: 5824703
    Abstract: A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung, or hyperinflated lung syndrome, and instilling a minimum effective dose of a perfluorochemical liquid or emulsion through the trachea for coating the alveolar sacs of a lung of the mammal. The preferred perfluorochemicals have a very low vapor pressure to avoid inducing hyperinflated lung syndrome and are supplied in a minimum effective dosage sufficient to coat the inner lung surfaces. The perfluorochemicals are permeable to the ambient gas and reside substantially permanently within the alveolar sacs without inducing hyperinflated lung syndrome. The liquid is instilled in an amount sufficient to enable the animal to breathe the ambient gas normally with O.sub.2 /CO.sub.2 blood gas exchange. Effective coating of the lungs with a small (generally <0.
    Type: Grant
    Filed: December 27, 1996
    Date of Patent: October 20, 1998
    Assignee: Synthetic Blood International, Inc.
    Inventor: Leland C. Clark, Jr.
  • Patent number: 5733939
    Abstract: A method for reducing the inflammatory response in tissues of a patient, by contacting the tissue with an effective, inflammation-reducing amount of a liquid or gaseous fluorocarbon.
    Type: Grant
    Filed: November 22, 1995
    Date of Patent: March 31, 1998
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Bradley Phillip Fuhrman, Stephen F. Flaim, Lynn Joanne Hernan, Frances Darey Nesti, Michele Cecile Papo, David Marc Steinhorn
  • Patent number: 5726209
    Abstract: Biocompatible fluorocarbon emulsions are utilized to inhibit the removal of endogenously produced nitric oxide from the bloodstream, and to thereby inhibit vascular stenosis, vasoconstriction, and any other physiological condition or disorder arising in whole or in part from a deficiency of endogenous nitric oxide.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 10, 1998
    Assignee: Alliance Pharmaceutical Corp.
    Inventors: Stephen F. Flaim, Jean G. Riess
  • Patent number: 5684050
    Abstract: Stable emulsions of highly fluorinated organic compounds for use as oxygen transport agents, "artificial bloods" or red blood cell substitutes and as contrast agents for biological imaging. The emulsions comprise a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly soluble in water, a surfactant and water.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: November 4, 1997
    Assignee: HemaGen/PFC
    Inventors: Leland C. Clark, Jr., Robert Francis Shaw
  • Patent number: 5670495
    Abstract: This invention is directed to a method of attenuating or preventing the adverse side-effects of a perfluorochemical (PFC) emulsion on the hemostatic system and serum chemistry of an animal. The method includes intravenously administering a corticosteroid to an animal prior to intravenous administration of a PFC emulsion, in an amount sufficient to improve the adverse effects of the PFC upon the hemostatic system and serum triglyceride/enzyme levels of the animal. After administration of the corticosteroid, the PFC emulsion is administered intravenously. Preferably, the corticosteroid is dexamethasone, and the PFC is perfluorodichlorooctane.
    Type: Grant
    Filed: April 25, 1996
    Date of Patent: September 23, 1997
    Assignee: HemaGen/PFC
    Inventors: Thomas H. Goodin, Robert J. Kaufman
  • Patent number: 5635539
    Abstract: Stable emulsions of highly fluorinated organic compounds for use as oxygen transport agents, "artificial bloods" or red blood cell substitutes and as contrast agents for biological imaging. The emulsions comprise a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly soluble in water, a surfactant and water.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: June 3, 1997
    Assignee: HemaGen/PFC
    Inventors: Leland C. Clark, Jr., Robert F. Shaw
  • Patent number: 5607979
    Abstract: Creams formed from about 35% to about 50% fine particulates of certain poly(tetrafluoroethylene) (PTFE) resins dispersed in perfluorinated polyether oils having viscosities from about 20 cSt to about 350 cSt afford good protection against chemical warfare agents such as sulfur mustard (HD), lewisite (L), sulfur mustard/Lewisite mixtures (HL), pinacolyl methylphosphonofluoridate (soman or GD), thickened soman (TGD) and O-ethyl S-2-diisopropylaminoethyl methylphosphonothiolate (vx).
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: March 4, 1997
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventor: Michael J. McCreery
  • Patent number: 5480914
    Abstract: Nonaqueous thixotropic drug delivery vehicles for use in aqueous physiological systems are disclosed comprising a substantially homogeneous dispersion of at least one suspending aid in a nonaqueous perfluorocarbon or fluorinated silicone liquid carrier. Pharmaceutical compounds may be incorporated to provide thixotropic pharmaceutical compositions having improved delivery profiles and high drug localization. The thixotropic compositions act as free-flowing, drop-instillable liquids upon the application of stress yet behave as a visco-elastic material when at rest. Due to these thixotropic properties the pharmaceutical compositions have improved bioavailability, are capable of low dose volume delivery, and do not degrade the incorporated therapeutic or diagnostic compounds making them well suited for multidose packaging and administration.
    Type: Grant
    Filed: May 6, 1994
    Date of Patent: January 2, 1996
    Assignee: Allergan, Inc.
    Inventor: David L. Meadows
  • Patent number: 5470885
    Abstract: A method for reducing the inflammatory response in tissue of a patient, by contacting the tissue with an effective, inflammation-reducing amount of a liquid or gaseous fluorocarbon.
    Type: Grant
    Filed: September 29, 1993
    Date of Patent: November 28, 1995
    Assignee: The Research Foundation of the State University of New York
    Inventors: Bradley P. Fuhrman, Stephen F. Flaim, Lynn J. Hernan, Frances D. Nesti, Michele C. Papo, David M. Steinhorn
  • Patent number: 5434191
    Abstract: A blood substitute employs combinations of fluoro or perfluorochemicals capable in the presence of emulsifying agents of forming emulsions stable at room temperature and possessing enhanced oxygen carrying capacity; the invention enables preparation of an improved blood substitute, with improved O.sub.2 carrying capacity and stability, as well as lessened anaphylactoid reaction.
    Type: Grant
    Filed: August 23, 1993
    Date of Patent: July 18, 1995
    Assignee: International Therapeutics Inc.
    Inventors: Walter B. Dandliker, W. Keith R. Watson, Thomas C. Drees
  • Patent number: 5374624
    Abstract: The present invention relates to fluorochemical blood substitutes used for preserving mammalian tissue having lysophosphatidyl compounds in non-toxic concentrations. More specifically, the invention relates to aqueous fluorochemical emulsions of a fluorochemical and an emulsifier useful as oxygen delivery agents and methods of preserving tissue in investigational and clinical settings, particularly those settings involving in in vivo transfusion, cardiac and other organ preservation, and in vitro organ perfusion.
    Type: Grant
    Filed: August 11, 1993
    Date of Patent: December 20, 1994
    Inventor: Leigh D. Segel
  • Patent number: 5244924
    Abstract: A diluent for perfluorocarbons used for retinal unfolding (unfolding PFCL), consisting of a perfluorocarbon (diluent PFCL), which has a low viscosity and is volatile at room temperature, with a boiling point between body temperature (about 38.degree. C.) and 100.degree. C., for removing residual quantities of unfolding PFCL from the eye after performance of a retinal unfolding treatment. A method of treatment consisting of introducing into an eye the above diluent for the above purpose.
    Type: Grant
    Filed: January 24, 1992
    Date of Patent: September 14, 1993
    Assignee: Adatomed Pharmazeutische und Medizintechnische Gesellschaft mbH
    Inventor: Hasso Meinert
  • Patent number: 5234680
    Abstract: The present invention is directed to biological compounds derivatized so as to contain at least one perfluoro-t-butyl moiety for use in fluorine-19 NMR and/or MRI studies. The perfluoro-t-butyl (PFTB) moiety, ##STR1## is an excellent reporter group for fluorine-19 NMR/MRI. It is a source of nine magnetically equivalent fluorine nuclei which generate a single intense resonance for easy detection in spectroscopy or imaging. This signal is a sharp singlet, not split by neighboring nuclei or spread over a wide frequency range and eliminates any chance of ghost images which might arise from multiple resonances. These spectral properties ensure a maximum signal-to-noise ratio (S/N) for readily detecting this moiety. The foregoing allows either reduction in the concentration of the derivatized compound, ability to use MRI instruments with lower field strengths, a reduction in imaging times, or a combination of the foregoing as a result of this moiety producing a single, sharp, intense resonance.
    Type: Grant
    Filed: September 19, 1991
    Date of Patent: August 10, 1993
    Assignees: Johns Hopkins Univ., Towson State University
    Inventors: Walter J. Rogers, Jr., Thomas S. Everett